First clinical observations of HER2 specific [111In]ABY-025 metastatic detection capability in females with metastatic breast cancer
Dan Sandberg(Uppsala University), Henrik Lindman(Uppsala University), Ulrike Garske(Uppsala University Hospital), Anders Wennborg(Affibody (Sweden)), Vladimir Tolmachev(Uppsala University), Joachim Feldwisch(Uppsala University), Jörgen Carlsson(Uppsala University Hospital), Jens Christian Hedemann Sørensen(Uppsala University)
Unknown
May 1, 2012
Cited by 7
Related Papers
Breast Cancer in Young Women: Poor Survival Despite Intensive Treatment
|PLoS ONE|2009|504
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial
|The Lancet|2000|343
Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [<sup>68</sup>Ga]ABY-025 Affibody PET/CT
|Theranostics|2015|269
First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the <sup>111</sup>In-ABY-025 Affibody Molecule
|Journal of Nuclear Medicine|2014|260